Evidence map›Paper›PMID 32910349›Full record

ReviewCurrent cardiology reports2020

Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.

Juan Simon Rico-Mesa, Averi White, Ashkan Ahmadian-Tehrani, Allen S Anderson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 5 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 5 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Observational
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2025
    Review
  15. MyocardialAntioxidants (Basel, Switzerland) · 2025
    Article
  16. Review
  17. Article
  18. Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Juan Simon Rico-MesaDepartment of Medicine, Division of Internal Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
Averi WhiteDepartment of Medicine, Division of Internal Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
Ashkan Ahmadian-TehraniDepartment of Medicine, Division of Internal Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
Allen S AndersonDepartment of Medicine, Division of Cardiovascular Diseases, University of Texas Health San Antonio, 7703 Floyd Curl Drive, MC 7872, San Antonio, TX, 78229, USA. Andersona4@uthscsa.edu.
The University of Texas at San Antonio · USThe University of Texas Health Science Center at San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewWe aim to review the mechanism of action and safety profile of mineralocorticoid receptor antagonists (MRAs) and discuss the differences between selective and non-selective MRAs. More specifically, finerenone is a new medication that is currently under investigation for its promising cardiovascular and nephrological effects. RECENT

findingsMRAs are well known for their utility in treating heart failure, refractory hypertension, and diverse nephropathies, namely, diabetic nephropathy. As their name denotes, MRAs inhibit the action of aldosterone at the mineralocorticoid receptor, preventing receptor activation. This prevents remodeling, decreases inflammation, and improves proteinuria. There are not significant differences in outcomes between selective and non-selective MRAs. A new selective MRA named finerenone (originally BAY 94-8862) has shown promising results in several trials (ARTS-HF and ARTS-DN) and smaller studies. Finerenone may have a dose-dependent benefit over older MRAs, decreasing rates of albuminuria and levels of BNP and NT-ProBNP without causing a significant increase in serum potassium levels. This medication is not yet approved as it is still in phase 3 clinical trials (FIGARO-DKD and FIDELIO-DKD trials). MRAs are beneficial in several disease states. Newer medications, such as finerenone, should be considered in patients with heart failure and diabetic nephropathy who may benefit from a reduction in albuminuria and BNP/NT-ProBNP. Data surrounding finerenone are limited to date. However, results from ongoing clinical trials, as well as new trials to evaluate use in other pathologies, could validate the implementation of this medication in daily practice.

Indexed as

Diabetic NephropathiesHeart FailureHumansMineralocorticoid Receptor AntagonistsNaphthyridinesSpironolactonefinerenoneMineralocorticoid Receptor AntagonistsNaphthyridinesSpironolactoneAldosteroneBAY 94-8862EplerenoneFinerenoneMineralocorticoid receptor antagonistsSpironolactone

Identifiers

PMID32910349
OpenAlexW3086237503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.